GSK may be tempted back to bid for ARIAD by rumours of AstraZeneca interest
GlaxoSmithKline (GSK) is rumoured to be a potential bidder for the Nasdaq-listed oncology group ARIAD Pharmaceuticals, The Independent reported.
The market report noted speculation that UK-listed GSK might be prompted to look again at ARIAD following recent chatter that rival UK-based pharma group AstraZeneca is in the frame as a prospective ARIAD acquirer.
GSK was rumoured to be eyeing Cambridge, Massachusetts-based ARIAD early this year, the report said.
Independent